[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of California, Davis\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":642},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,132,0,25,[9,47,75,108,132,158,186,212,232,249,277,303,328,350,371,390,415,437,470,493,520,544,564,587,613],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100652886","virtual-reality-vr-audiovisual-distraction-to-reduce-pain-and-anxiety-for-prone-pain-procedures-100652886",false,"NCT07779083","Virtual Reality (VR) Audiovisual Distraction to Reduce Pain and Anxiety for Prone Pain Procedures","Inclusion Criteria:\n\n* Patients aged 18 years old or older\n* Male and female gender\n* Referred to UC Davis Pain Medicine Clinic and require a prone pain procedure\n* English speaking and with the ability to understand oral and written instructions\n\nExclusion Criteria:\n\n* Pregnant women\n* Prisoners\n* Patients who have high risk of motion sickness\n* Seizure disorder\n* Visual\u002Fhearing impairment","ALL","18 Years",{"count":19,"type":20},230,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study evaluates whether virtual reality (VR) audiovisual distraction can reduce pain, anxiety, and the need for pain and anxiety medications during prone pain procedures, compared to standard care alone. The trial design is a two-arm, parallel assignment, randomized controlled trial at a single site, the UC Davis Pain Medicine Clinic. Patients will be randomized in a 1:1 allocation to the intervention (commercially available virtual reality headset (Meta Quest 3) with audiovisual calming nature scene and an ergonomic cushion\u002Fsupport) vs control (standard medical care). The primary outcome will be a composite outcome analyzed using the Win Ratio method comparing opioid\u002Fsedative medication use, intra-procedural pain scores, and intra-procedural anxiety scores between groups. Approximately 230 people at UC Davis are expected to participate (Up to 20 patients for the preliminary run-in period to acclimatize research and clinical staff and 210 total for the randomized clinical trial). Each participant's involvement consists of one visit, estimated at 30 minutes.",[26,27],"Procedural Pain","Procedural Anxiety",[29,30,31,32,33],"Virtual Reality","Pain","Anxiety","Prone Pain Procedure","Audiovisual Distraction","NOT_YET_RECRUITING","2026-08-18",{"date":37,"type":38},"2026-08-21","ACTUAL",{"date":40,"type":20},"2026-10",{"date":42,"type":20},"2028-12",{"name":44,"class":45},"University of California, Davis","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100393996","patient-derived-xenografts-to-reduce-cancer-health-disparities-100393996","NCT04410302","Patient-Derived Xenografts to Reduce Cancer Health Disparities","University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities","Inclusion Criteria:\n\n* Patient receiving treatment for the above 4 cancers (bladder cancer, lung cancer, gastric\u002Fstomach cancer, and liver cancer)\n* Signed informed consent that will be put on file\n\nExclusion Criteria:\n\n* No informed consent obtained\n* Specimen unacceptable\u002Fdegraded\u002Fetc.\n* Individuals who are not yet adults (infants, children, teenagers)\n* Pregnant women\n* Prisoners\n* Adults unable to consent","21 Years","100 Years",{"count":57,"type":20},500,"OBSERVATIONAL","This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial\u002Fethnic minorities. Understanding the genetic and response differences among racial\u002Fethnic minorities may help researchers enhance the precision of therapeutic treatments.",[61,62,63,64,65],"Bladder Carcinoma","Gastric Carcinoma","Liver and Intrahepatic Bile Duct Carcinoma","Lung Carcinoma","Malignant Neoplasm","RECRUITING",{"date":68,"type":38},"2026-08-20",{"date":70,"type":38},"2019-11-12",{"date":72,"type":20},"2027-06",{"name":44,"class":45},2,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":46},"100641721","goji-berry-and-vasomotor-symptoms-pilot-study-100641721","NCT07660315","Goji Berry and Vasomotor Symptoms Pilot Study","GOJI-VMS Pilot Study: Effects of Two Goji Berry Powder Forms on HDL Function, Vasomotor Symptoms, and Cognitive Performance","GOJI-VMS","Inclusion Criteria:\n\n* Adult women aged 40-65 years\n* Peri- or postmenopausal with vasomotor symptoms (hot flashes) occurring ≥4 days\u002Fweek over the past 2 weeks\n* Willing to consume one mug-cake daily for 30 days\n* Willing to complete daily VMS symptom tracking on a smartphone\n* Hormone therapy (HRT) is allowed if the dose has been stable for ≥8 weeks and hot flashes are still present\n\nExclusion Criteria:\n\n* Combined intake of \\>5 servings of eggs or lutein\u002Fzeaxanthin-rich vegetables per week\n* Current pregnancy or breastfeeding\n* Known allergy or intolerance to goji (Lycium barbarum) or to key mug-cake ingredients (e.g., wheat\u002Fgluten, dairy, and eggs)\n* Current use of warfarin (goji has reported interactions with anticoagulants); other anticoagulants will be reviewed case-by-case\n* Uncontrolled thyroid disease or other medical conditions likely to confound VMS assessment\n* Initiation or planned change of HRT, GLP-1 agonists, or other medications known to affect lipid metabolism or VMS during the 30-day study\n* Current participation in another interventional study\n* Any condition that, in the judgment of investigators, makes participation unsafe or data interpretation unreliable",true,"FEMALE","40 Years","65 Years",{"count":88,"type":20},6,[23],"The goal of this clinical trial is to compare two forms of goji berry powder-whole goji berry powder and goji juice powder-in peri- and postmenopausal women aged 40-65 years who experience frequent vasomotor symptoms (hot flashes). The study aims to determine which formulation is more promising for a future larger trial by evaluating effects on HDL cholesterol function, vasomotor symptoms, cognitive performance, and participant acceptability.\n\nThe main questions it aims to answer are:\n\nDoes whole goji berry powder produce a greater improvement in HDL cholesterol efflux capacity (CEC) over 30 days compared with goji juice powder? Are changes in HDL function associated with changes in hot flash burden, cognitive performance, and self-reported cognitive symptoms?\n\nResearchers will compare participants assigned to whole goji berry powder with participants assigned to goji juice powder to evaluate differences in HDL function, vasomotor symptoms, cognitive outcomes, and intervention acceptability.\n\nParticipants will:\n\nConsume one mug cake containing their assigned goji powder daily for 30 days. Record hot flash frequency, duration, and severity using a smartphone-based electronic diary.\n\nAttend study visits at baseline, Day 15, and Day 30. Provide fasting blood samples at baseline and Day 30 for assessment of HDL cholesterol efflux capacity and cardiometabolic biomarkers.\n\nComplete computerized cognitive testing (TabCAT) at baseline and Day 30. Complete questionnaires assessing menopause-related quality of life, brain fog, mental alertness, physical activity, and study acceptability.",[92],"Vasomotor Symptoms",[94,92,95,96,97,98,99,100],"Goji Berry","Hot flush","Lutein","Zeaxanthin","Carotenoids","HDL","Cholesterol Efflux Capacity","2026-08-15",{"date":35,"type":38},{"date":104,"type":20},"2026-10-25",{"date":106,"type":20},"2027-10-31",{"name":44,"class":45},{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":83,"sex":84,"minAge":114,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100632920","expediting-pregnancy-of-unknown-location-risk-stratification-using-the-rom-plus-point-of-care-test-100632920","NCT07519954","Expediting Pregnancy of Unknown Location Risk Stratification Using the ROM-Plus Point of Care Test","Inclusion Criteria:\n\n* PUL diagnosis in the UC Davis Emergency Department or Obstetrics and Gynecology Office\n* Vaginal bleeding\n* Clinically stable\n* English-speaking","15 Years",{"count":116,"type":20},122,"The goal of this study is to learn if the ROM-Plus bedside test can effectively triage patients who present with pregnancy of unknown location (PUL) and vaginal bleeding as high or low risk for ectopic pregnancy. The main question to answer is:\n\nCan the ROM-Plus bedside test effectively risk-stratify patients who present with PUL and vaginal bleeding as high or low risk for ectopic pregnancy after a single clinical encounter.\n\nParticipants will have a vaginal swab collected at the time of presentation.",[119],"Pregnancy of Unknown Location (PUL)",[121,122,123,124,125],"pregnancy of unknown location (PUL)","risk-stratification","ROM-Plus test","ectopic pregnancy","vaginal bleeding",{"date":35,"type":38},{"date":128,"type":20},"2026-10-01",{"date":130,"type":20},"2028-10",{"name":44,"class":45},{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":143,"conditions":144,"keywords":147,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":155,"leadSponsor":157,"locationsCount":74},"100622526","phase-2-efficacy-and-safety-of-topical-timolol-in-secondary-intention-surgical-wounds-healing-100622526","NCT07384767","Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing","Efficacy and Safety of Topical Timolol in the Treatment of Cutaneous Surgical Wounds Left to Heal by Secondary Intention","Inclusion Criteria:\n\n1. Male or female subject of any race 18 years old or older\n2. Patient opt to heal by secondary intention healing after discussion of reconstructive options following excision\n3. Patients undergoing Mohs micrographic surgery, standard surgical excision, or electrodesiccation and curettage (ED\\&C) whose wounds are managed by secondary intention healing.\n4. Willing to send photos of ulcer at 3 week intervals with ruler measuring length by width\n5. Able to give informed consent themselves\n\nExclusion Criteria:\n\n1. Cyst excisions (due to concern for inflammation)\n2. Site shows evidence of infection (defined as a moderate or severe rating of all of the following clinical signs\u002Fsymptoms: 1) increased warmth, 2) increased pain, 3) erythema, and 4) malodorous exudate at Screening or at Randomization (Visit 1), OR total organism count \\> 1 x 105 colony forming units (CFU) from the screening visit study ulcer culture sample)\n3. Severe COPD\u002Fasthma\u002Fcardiac arrhythmia\n4. Hx of documented beta blocker allergy\n5. Cognitive impairment\n6. Has medically documented history of Human Immunodeficiency Virus (HIV)\n7. Has active malignancy on the study limb\n8. Has immunodeficiency as defined by serum IgG, IgA, and IgM less than one-half the lower limit of normal\n9. Has severe protein malnutrition as defined by serum albumin \\\u003C 2.5 g\u002FdL\n10. Has serum aspartate aminotransferase (AST, SGOT, GOT) or serum alanine aminotransferase (ALT, SGPT, GPT) levels greater than twice the upper limit of normal\n11. Has fatigue, palpitations, dyspnea, and\u002For angina at rest\n12. Has a medically documented or self-reported history, within the previous 12 months from date of Screening Visit, of alcohol or drug abuse, particularly methadone or heroin\n13. Has received previous treatment with the following during the 60 days prior to Screening: Immunosuppressive agents, radiation, chemotherapy, growth factors (epidermal growth factor, tumor necrosis factor, transforming growth factor, platelet derived growth factor, etc.)\n14. Has received previous treatment with the following during the 30 days prior to screening: the site of the study ulcer, split- or full-thickness skin graft at the site of the study ulcer, biologically-active (or engineered) cellular or acellular product(s) at the site of the study ulcer, investigational drug or device\n15. Has history of bradycardia (heart rate less than 60)\n16. Has ESR\\>70mm\u002Fhr and CRP\\>100 mg\u002FL at time of screening\n17. Has medically documented history of hypotension\u002Forthostatic hypotension and\u002For symptomatic hypotension (systolic blood pressure below 90 and diastolic blood pressure less than 60). (Note: There is no standard testing regimen protocol for orthostatic hypotension, even for patients starting on oral timolol)\n18. Currently taking asthma or COPD medications (as documented in chart)\n19. Has a medically documented diagnosis of myasthenia gravis, untreated hyperthyroidism, , Type 2, Type 3 heart block, cardiogenic shock, overt cardiac failure\n20. Female who is pregnant or refuses to use adequate contraceptive methods and is of childbearing age during the trial\n21. Prisoners, institutionalized individuals or vulnerable population",{"count":140,"type":20},220,[142],"PHASE2","The purpose of this research study is to evaluate the efficacy and safety of topical timolol 0.5% for secondary intention wound healing following 1) Mohs micrographic surgery, 2) standard surgical excision, OR 3) electrodesiccation and curettage (ED\\&C). Please note that healing by secondary intention refers to when a wound heals naturally without surgical closure.\n\nTo evaluate the efficacy of topical timolol 0.5%, 220 participants will be recruited. Participants will be placed into one of two groups: The treatment group or the control group.\n\n1. The treatment group will receive a topical timolol 0.5% solution, which will be applied to their wound daily for 12 weeks.\n2. The control group will receive standard care with the addition of hydrogel, which will also be applied to their wound daily for 12 weeks.\n\nDuring this 12-week period, both groups will be required to upload photos of their wound healing to their MyChart account at weeks 3, 6, 9, and 12. These photos will be reviewed by the investigator to assess wound healing. Re-epithelialization and earlier complete wound healing will be compared between both groups to determine the efficacy of topical timolol 0.5% solution compared to the standard of care.",[145,146],"Mohs Micrographic Surgery","Excision Margin",[148,149,150,151,152],"standard surgical excision","Mohs micrographic surgery","electrodesiccation and curettage","timolol","randomized",{"date":35,"type":38},{"date":128,"type":20},{"date":156,"type":20},"2027-12-31",{"name":44,"class":45},{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":171,"conditions":172,"keywords":176,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":46},"100617708","phase-4-dopamine-vs-norepinephrine-for-hypotension-in-neonates-with-pulmonary-hypertension-done-100617708","NCT07322133","Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)","Dopamine vs. Norepinephrine in Term and Late Preterm Neonates With Hypoxemic Respiratory Failure and Systemic Hypotension Due to Pulmonary Hypertension: A Pilot Trial","DONE","Inclusion Criteria:\n\n1. Postmenstrual age \\> 34 6\u002F7 weeks and Postnatal age ≤ 28 days\n2. On respiratory support (Invasive mechanical ventilation, NIPPV, CPAP, HFNC ≥ 2 LPM) and FiO2 ≥ 0.3\n3. Echocardiographic evidence of pulmonary hypertension\n4. Mean arterial pressure below the threshold for gestational age despite a 10-20 mL\u002Fkg fluid bolus\n\nPermissible Comorbidities: CDH, trisomy 21, HIE on hypothermia, PDA, PFO\u002FASD, VSD \\\u003C 2 mm\n\nExclusion Criteria:\n\n1. Gestational age \\\u003C 32 weeks\n2. Severe hypoxic respiratory failure (OI \\> 35 or SpO2 \\\u003C 75% on 100% FiO2 for \\> 60 minutes)\n3. Lethal anomalies (e.g., trisomy 13 or 18)\n4. Complex congenital heart disease beyond specified criteria","28 Days",{"count":168,"type":20},30,[170],"PHASE4","This pilot randomized clinical trial compares dopamine and norepinephrine as first-line vasoactive therapies in term and late preterm neonates with pulmonary hypertension associated with hypoxemic respiratory failure and systemic hypotension. Systemic hypotension is a common and clinically significant complication of persistent pulmonary hypertension of the newborn (PPHN) and frequently requires vasopressor support to maintain adequate systemic perfusion. Dopamine is commonly used in this setting; however, prior animal experimental and clinical data suggest it may increase pulmonary vascular resistance, potentially worsening right ventricular afterload and hypoxemia. Norepinephrine may preferentially increase systemic vascular resistance with less effect on the pulmonary circulation. This study evaluates short-term hemodynamic and oxygenation responses following initiation of dopamine or norepinephrine.",[173,174,175],"Hypotension and Shock","Pulmonary Hypertension of the Newborn (PPHN)","Hypoxemic Respiratory Failure",[177,178,179],"Pulmonary Hypertension","Systemic Hypotension","Vasopressor",{"date":35,"type":38},{"date":182,"type":20},"2026-10-30",{"date":184,"type":20},"2027-06-30",{"name":44,"class":45},{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":192,"targetDuration":4,"studyType":21,"phases":194,"briefSummary":196,"conditions":197,"keywords":200,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":46},"100563835","phase-2-transnasal-sphenopalatine-ganglion-block-for-treatment-of-acute-subarachnoid-hemorrhage-associated-headache-100563835","NCT06621329","Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache","Inclusion Criteria:\n\n* Acute subarachnoid hemorrhage\n* Age greater than 18 years\n* Secured aneurysm\n* Patient can verbalize pain score to clinician, nurse, medical translator, or surrogate decision\n* maker\n* Patient or surrogate decision maker is available to consent\n\nExclusion Criteria:\n\n* Less than 18 years old\n* Unsecured aneurysm\n* Pregnant or lactating\n* Prisoner\n* Unable to verbalize pain score to clinician, nurse, medical translator, or surrogate decision maker\n* Nasal or facial trauma or surgery within the last three months\n* Allergy to lidocaine, bupivacaine, or dexamethasone\n* Patient is unable to consent and no available surrogate decision maker",{"count":193,"type":20},40,[142,195],"PHASE3","The study titled \\"Transnasal sphenopalatine ganglion block for treatment of acute subarachnoid hemorrhage associated headache\\" is a randomized controlled pilot study aimed at evaluating the efficacy of a transnasal sphenopalatine ganglion (SPG) block in addition to standard pain medication for reducing headache severity in patients with acute subarachnoid hemorrhage (aSAH). The study also examines whether this intervention can reduce opioid requirements during hospitalization and upon discharge.",[198,199],"SAH (Subarachnoid Hemorrhage)","Headache",[201,202,203,204,205],"aSAH","peripheral nerve block","sphenopalatine ganglion","subarachnoid hemorrhage","headache",{"date":35,"type":38},{"date":208,"type":38},"2024-10-17",{"date":210,"type":20},"2027-10",{"name":44,"class":45},{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":21,"phases":221,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":46},"100550963","early-phase-1-neuroflipp-parametric-pet-of-neuroinflammation-in-fatty-liver-disease-100550963","NCT06453915","NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease","NeuroFLiPP - Parametric PET of Neuroinflammation in Fatty Liver Disease","Inclusion Criteria:\n\n* Participants \\>=18 years age\n* Participants who have or have planned a liver biopsy as:\n\n  * standard of care for fatty liver disease with risk factors for metabolic dysfunction-associated steatohepatitis (MASH), or\n  * as part of another Clinical Trials study for MASH, or\n  * standard of care prior to undergoing bariatric surgery\n  * Liver biopsy needs to be within 6 months of planned study-related imaging\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* History of alcohol abuse, chronic hepatitis B or C, or other chronic liver disease other than non-alcoholic fatty liver disease.\n* Uncontrolled claustrophobia\n* Body weight \\>225 kg due to limitations of the scanner bed\n* Pregnant or breast-feeding (due to risks of ionizing radiation; urine pregnancy test will be administered prior to start of each PET\u002FCT session for all participants between 18 to 60 years old who are able to get pregnant, unless documented hysterectomy is available)\n* Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.\n* Prisoners\n* Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.\n* Pre-existing neurodegenerative disorders and dementia\n* Significant history of major skull concussion or repetitive head trauma\n* Currently on anticoagulant therapy\n* Metal implants (e.g., pacemaker) or claustrophobia that would preclude MRI scans",{"count":220,"type":20},12,[222],"EARLY_PHASE1","Alzheimer's Disease and related dementias (ADRD) affect about 6 million people in the U.S. and are the fifth leading cause of death for adults over 65. Recent research is investigating how chronic liver diseases like Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects one-third of the U.S. population, might influence ADRD through the liver-brain axis. MASLD shares risk factors with Alzheimer's, such as diabetes and hypertension, and studies have linked MASLD to increased risks of cognitive decline and ADRD. Mouse-model studies suggest that chronic liver inflammation in MASLD can induce neuroinflammation and accelerate Alzheimer's pathology, highlighting the importance of studying the liver-brain connection to identify new therapeutic targets for ADRD.\n\nThe goal of this research is to develop a practical PET imaging method using 18F-FDG to simultaneously assess liver and brain inflammation in patients with MASLD-related ADRD. This approach leverages dynamic FDG-PET scanning and advanced tracer kinetic modeling to quantify glucose transport, overcoming limitations of traditional imaging methods that cannot noninvasively assess chronic liver inflammation. The new method aims to enable comprehensive imaging of liver-brain inflammation crosstalk, validated against the 18F-DPA-714 radiotracer. Success in this project could provide a valuable imaging tool for linking liver inflammation with neuroinflammation and cognitive decline, advancing clinical research and potentially uncovering new pathways for ADRD treatment",[225],"Positron Emission Tomography",{"date":35,"type":38},{"date":228,"type":38},"2025-04-30",{"date":230,"type":20},"2027-07",{"name":44,"class":45},{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":238,"targetDuration":4,"studyType":21,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":248,"locationsCount":46},"100226959","phase-2-immunologic-response-to-pneumococcal-polysaccharide-vaccine-in-splenic-injury-patients-100226959","NCT02232191","Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients","Inclusion Criteria:\n\n* Adult trauma patients (aged 18 to 65 years old) sustaining a splenic injury.\n\nExclusion Criteria:\n\n* Ages less than 18 and greater than 65\n* Initial planned nonoperative management patient who subsequently undergoes embolization or splenectomy will be withdrawn from the study.",{"count":239,"type":20},75,[142],"Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infections, though they do not so with certainty. Trauma patients who sustain an injury to their spleen currently have three treatment options available for the treating surgeon - nonoperative management, embolization, or removal of the spleen. The purpose of this study is to investigate the antibody response to pneumococcal vaccine in patients undergoing these modes of therapy.",[243],"Asplenia",{"date":35,"type":38},{"date":246,"type":4},"2014-12",{"date":230,"type":20},{"name":44,"class":45},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":83,"sex":16,"minAge":257,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":21,"phases":261,"briefSummary":262,"conditions":263,"keywords":266,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":74},"100424234","phase-2-senicapoc-in-alzheimers-disease-100424234","NCT04804241","Senicapoc in Alzheimer's Disease","Proof of Mechanism Study of Senicapoc in Mild or Prodromal Alzheimer's Disease","Senicapoc","Inclusion Criteria:\n\n* Age 55-85\n* Fluent in either English or Spanish\n* Willing to be randomized to active drug (10 mg Senicapoc) vs. placebo (3:1 ratio)\n* Clinical Dementia Rating (CDR) global score of 1 or 0.5\n* Education adjusted scores between 12-28 on the Montreal Cognitive Assessment (MoCA) at the Screening visit.\n* A consensus clinical diagnosis of either amnestic Mild Cognitive Impairment (MCI) or mild AD dementia. Diagnoses are made by a comprehensive case conference review for all participants in the ADRC longitudinal cohort and all CADC referrals, resulting in a consensus diagnosis made according to current research criteria. For patients referred from other clinics, the case will be reviewed by a study physician and neuropsychologist and only patients who satisfy criteria for probable AD (McKhann et al 1984) or amnestic MCI (Petersen et al 2004) will be eligible for enrollment.\n* Vision (with or without correction) of at least 20\u002F50 for distant vision\n* All participants will need a study partner informant who has at least 6 hours of contact per week with the participant. The study partners are used to help answer questions on the subject's behalf, since many of them will be impaired and may need assistance with providing accurate information. The study partners are not asked to provide any opinions or judgements about the subjects.\n* For Females of childbearing potential: Must agree to practice a highly effective method of contraception throughout the study until completion of the Week 78 follow up visit. Highly effective methods of contraception are those that alone or in combination result in a failure rate of less than 1% per year when used correctly and consistently.\n\nExclusion Criteria:\n\n* Unstable medical illnesses including hepatic insufficiency (elevated ALT, AST, or GGT; or low albumin attributable to liver disease), renal insufficiency (CK-EPI stage 4 or higher, or estimated GFR \\\u003C30)\n* Unstable ischemic cardiovascular disease, respiratory failure, moderate or severe congestive heart failure - New York Heart Association class III or IV, cancer, unstable hematologic disease or a life expectancy of \\\u003C3 years\n* Use of experimental AD treatments\n* Unable to undergo MRI scanning (e.g. pacemaker, metallic implants, severe claustrophobia)\n* History of chronic psychiatric illness (e.g. schizophrenia), any episode of major depression within last 2 years, or current Geriatric Depression Scale (GDS) \\> 6, any recent suicide attempts or suicidal ideation. Subjects with a diagnosis of bipolar disorder may be included if they have been clinically stable for a minimum of 3 years prior to the Screening visit. Clinical stability to be determined by the Principal Investigator.\n* History of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis), head trauma resulting in any persistent cognitive deficit\n* History of alcohol or drug abuse\u002Fdependence within the past 5 years\n* Known allergy to chemically related compounds (e.g. clotrimazole)\n* Lack of good venous access, such that multiple blood draws would be precluded\n* Regular use of any of these CNS active medications: benzodiazepines, antipsychotics, narcotics, or anti-epileptic drugs. Exceptions may be allowed by the Principal Investigator for regular use of low doses of CNS active medications. Subjects using any of these treatments will be instructed to hold their dose on the evening prior and the day of the efficacy visits (Baseline, Week 26 and Week 52). Stable doses (\\> 6 weeks) of cholinesterase inhibitors or memantine will be allowed, as will stable doses of anti-depressants.\n* Female subjects who are pregnant or breastfeeding or who plan to become pregnant during participation in this trial\n* Inability to swallow oral tablets\n\nExclusions for Cerebrospinal Fluid (CSF) Sub-study:\n\n* Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter\n* History of bleeding diathesis or coagulopathy,\n* On anticoagulant therapy (within 14 days of lumbar puncture (LP), including but not limited to warfarin, heparin, dabigatran, rivaroxaban, and apixaban,\n* Requires daily antiplatelet therapy, including but not limited to aspirin (unless \\\u003C 81mg\u002Fday), clopidogrel, dipyridamole, and ticlopiidinegrel. However, the investigators will not exclude those who can safely hold antiplatelet therapy for 7 days prior to LP. Safety will be determined by the participant's Primary Care Provider and study PI.\n* For those who take antiplatelet therapy intermittently (e.g. aspirin as needed for pain), the investigators will exclude any doses within 48 hours of the LP or more than two dosses within 7 days of LP.\n* platelet count less than the lower limit of normal (platelet counts between 100,000 and 150,000 mm3 are permissible as long as the investigator confirms there is no evidence of current bleeding diathesis or coagulopathy)\n* The investigators will require INR\u002FPT and aPTT labs to be done within 14 days of LP and will exclude those with INR \\> 1.30 or abnormally elevated aPTT.\n\nExclusions for PET Sub-Study:\n\n* Does not have good venous access, such that multiple blood draws would be precluded\n* Prior radiation exposure of \\> 2 rem total within last 12 months.\n* Probable AD dementia patients with a global cortical SUVr \\\u003C 1.08.","55 Years","85 Years",{"count":260,"type":20},55,[142],"Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove biological activity and target engagement in humans with early AD. The investigators will study up to 55 patients over 52 weeks, with primary outcomes being Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) scores and blood and cerebrospinal fluid (CSF) markers of neuroinflammation. This pilot study will provide an estimate of treatment effect size on cognitive trajectory, daily function, and brain atrophy.",[264,265],"Mild Cognitive Impairment","Alzheimer Disease",[267,268,255],"Amnestic Mild Cognitive Impairment (MCI)","Mild AD dementia","2026-08-14",{"date":271,"type":38},"2026-08-17",{"date":273,"type":38},"2022-03-18",{"date":275,"type":20},"2027-12",{"name":44,"class":45},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":83,"sex":16,"minAge":285,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":21,"phases":289,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":46},"100580025","hpv-ends-here-increasing-uptake-of-the-hpv-vaccine-100580025","NCT06831929","HPV Ends Here: Increasing Uptake of the HPV Vaccine","Human Papillomavirus Ends Here: A Multilevel Intervention to Increase Uptake of the HPV Vaccine Among Adolescents","HPV","Inclusion Criteria:\n\n• Clinic patients between the ages of 10-12 who are eligible for the HPV vaccine\n\nExclusion Criteria:\n\n• Clinic patients who already received the HPV vaccine or with any contraindication to the HPV vaccine.","10 Years","12 Years",{"count":288,"type":20},2232,[23],"Develop, implement, and evaluate a culturally tailored multilevel intervention to increase uptake of the HPV vaccine among eligible patients ages 10-12 of the University of California, Davis Health Community Physician (UCDH CP) primary care practices using a randomized controlled trial design.",[292],"HPV Vaccine",[283,294],"Human Papillomavirus","2026-08-07",{"date":297,"type":38},"2026-08-11",{"date":299,"type":38},"2025-02-28",{"date":301,"type":20},"2026-12-31",{"name":44,"class":45},{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":310,"targetDuration":4,"studyType":21,"phases":312,"briefSummary":314,"conditions":315,"keywords":318,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":46},"100651500","phase-1-allogeneic-orca-q-stem-cell-transplant-for-the-treatment-of-relapsed-and-refractory-high-risk-multiple-myeloma-100651500","NCT07759102","Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma","A Phase I Study to Evaluate the Safety and Efficacy of ORCA-Q Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Relapsed\u002F Refractory High Risk Multiple Myeloma","Inclusion Criteria:\n\n* Ability to understand and sign informed consent\n* Age ≥ 18 years and ≤ 65 years\n* Patients should be in very good partial response (VGPR) (5% or less plasma cells in the marrow) or better response status at the time of stem cell transplant with no evidence of central nervous system (CNS) disease. Patients in complete response (CR) should have minimal residual disease (MRD) positivity\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1; or Karnofsky performance status (KPS) of ≥ 70%\n* ≥ 60 days washout period from the last dose of an anti-CD38 antibody before the allogeneic transplant\n* ≥ 6 months washout period from the last autologous transplant before the allogeneic transplant\n* Related or unrelated donors available as follows:\n\n  * Sibling donor who is a 7\u002F8 mismatched or 8\u002F8 matched for human leukocyte antigen (HLA)-A, -B, -C, -DRB1\n  * Matched unrelated donor who is a 7\u002F8 mismatched or 8\u002F8 matched for HLA-A, -B, -C, and -DRB1\n* A diagnosis of relapsed or refractory defined as:\n\n  * Primary refractory disease or relapse \\\u003C 12 months following initial therapy that includes an immunomodulatory agent, proteasome inhibitor, anti-CD38 monoclonal antibody, and corticosteroid\n  * Relapse \\\u003C 12 months after first autologous stem cell transplant\n  * Failing to achieve complete response or relapsing after chimeric antigen receptor (CAR)-T treatment or bispecific antibodies; or indicated but ineligible for either bispecific antibodies or CAR-T cells due to low blood counts\n  * No appropriate standard of care therapy per investigator\n* A diagnosis of ultra-high risk multiple myeloma defined as having at least one or more of these criteria:\n\n  * Biallelic TP53 inactivation\n  * ≥ 2 HRCAs: del(17p), TP53 mutation, t(4;14), t(14;16), t(14;20), gain(1q), amp(1q), del(1p32)\n  * Biallelic del(1p32)\n  * High-risk gene expression profile signature\n  * Extramedullary disease excluding intramedullary plasmacytoma with extraosseous extension and active CNS disease\n  * ≥ 2% circulating plasma cells\n* Creatinine clearance of ≥ 50 mL\u002Fmin as estimated by Cockcroft-Gault\n* Total bilirubin ≤ 1.5 times upper limit of normal (ULN) except in subjects with Gilbert's syndrome in whom total bilirubin ≤ 3 times ULN\n* Alanine transaminase (ALT\u002Fserum glutamic pyruvic transaminase \\[SGPT\\]) and aspartate aminotransferase (AST\u002Fserum glutamic oxaloacetic transaminase \\[SGOT\\]) ≤ 3 x the upper limit of normal (ULN) or ≤ 5 x ULN if documented liver involvement by disease\n* Estimated glomerular filtration rate (eGFR) \\> 50mL\u002Fminute. Creatinine clearance of ≥ 30 mL\u002Fmin is allowed in patients eligible for no tacrolimus immunosuppression\n* Pulmonary function as defined by diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥ 50%\n* Cardiac ejection fraction at rest ≥ 45% or shortening fraction of ≥ 27% by echocardiogram, or radionuclide scan (multigated acquisition scan \\[MUGA\\])\n* Corrected diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥ 50%\n* Individuals of childbearing potential or those with partners of childbearing potential must agree to use methods of contraception for the duration of study participation or be surgically sterilized\n* Stated ability and willingness to adhere to the study visit schedule and protocol requirements\n* DONOR: Ability to understand and sign informed consent\n* DONOR: Age ≥ 16 and ≤ 35 years at time of enrollment for unrelated donors and Age ≥ 16 and ≤ 50 years for related donors\n* DONOR: Either one of the following scenarios:\n\n  * Sibling donor who is a 7\u002F8 mismatched or 8\u002F8 matched for HLA-A, -B, -C, and -DRB1, all typed using deoxyribonucleic acid (DNA)-based high-resolution methods\n  * Unrelated donor who is 7\u002F8 mismatched or 8\u002F8 matched HLA-A, -B, -C, and -DRB1, all typed using DNA-based high-resolution methods\n* DONOR: Willing to donate stem cell mobilized mononuclear cells for up to two consecutive days\n* DONOR: Able to donate within the continental United States at a site that will employ a Spectra Optia Apheresis System for post-mobilization apheresis\n* DONOR: Meets federal eligibility criteria for donors of viable, leukocyte-rich cells or tissues and all relevant Food and Drug Administration (FDA) Guidance for Industry (Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products, 2007; Use of Donor Screening Tests to Test Donors of Human Cells, Tissues and Cellular and Tissue-Based Products for Infection with Treponema pallidum \\[syphilis\\], 2015; Use of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products, 2016; Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Living Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products \\[HCT\u002FPs\\], 2016)\n* DONOR: Donors determined to be ineligible, based on the results of required testing and\u002For screening, may nonetheless be included if either applies:\n\n  * The donor is a first-degree blood relative of the recipient\n  * Urgent medical need, meaning no comparable human cell product is available, and the recipient is likely to suffer death or serious morbidity without the human cell product, as attested by the investigator\n  * Meets any other criteria for donation as specified by standard National Marrow Donor Program (NMDP) guidelines (NMDP donors) or institutional standards (non-NMDP donors)\n\nExclusion Criteria:\n\n* Prior allogeneic hematopoietic cell transplantation (HCT)\n* Planned pharmaceutical in vivo or ex vivo T cell depletion, e.g., post-transplant cyclophosphamide (Cy), peri-transplant anti-thymocyte globulin (ATG), or alemtuzumab\n* Positive anti-donor HLA antibodies against a mismatched allele in the selected donor determined by either:\n\n  * A positive crossmatch test of any titer; or\n  * The presence of anti-donor HLA antibody to any HLA locus\n* Hematopoietic cell transplantation-specific Comorbidity Index (HCT-CI) \\> 4\n* Uncontrolled bacterial, viral, or fungal infections (currently taking antimicrobial therapy and with no clinical improvement) at time of enrollment\n* Seropositive for HIV-1 or -2, human T-cell lymphotropic virus (HTLV)-1 or -2\n* Documented allergy or documented hypersensitivity to iron dextran or bovine, murine, algal or Streptomyces avidinii proteins\n* Concurrent malignancies or active disease within 1 year, except non-melanoma skin cancers or any carcinoma in situ that have been curatively resected\n* History of idiopathic or secondary myelofibrosis\n* Individuals who are pregnant or breastfeeding\n* Any condition that would prohibit the understanding or rendering of informed consent\n* Any condition that in the opinion of the investigator would interfere with the subject's safety or compliance while on study\n* A diagnosis of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome\n* DONOR: Evidence of uncontrolled, active infection\n* DONOR: Seropositive for HIV-1 or -2, HTLV-1 or -2\n* DONOR: Positive for hepatitis B (HBV) surface antigen (HBsAg), total anti-hepatitis B core antibody (HBcAb, immunoglobulin \\[I\\]gG and IgM), HBV nucleic acid testing (NAT), anti-hepatitis C (HCV) antibody, or HCV NAT\n* DONOR: Aberrant CD45RA isoform expression\n* DONOR: Women who are pregnant or breastfeeding",{"count":311,"type":20},20,[313],"PHASE1","This phase I trial tests the effect of allogeneic Orca-Q stem cell transplant in treating patients with high-risk multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). An allogeneic (donor) transplant uses blood forming stem cells (graft) from a matched donor. When the healthy blood forming (stem) cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets and may help destroy any remaining cancer cells. Sometimes the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease \\[GVHD\\]). Orca-Q includes some T cells (a type a white blood cell) that are thought to help prevent some of the known complications as well as help attack the cancer cells. However, Orca-Q removes a specific type of T cell called naive T lymphocytes. Naive T cells may contribute to GVHD and are not thought to be required for the success of the treatment. Removing these cells may help reduce the frequency or severity of GVHD. Giving chemotherapy, such as thiotepa, busulfan, and fludarabine, before a donor stem cell transplant helps kill cancer cells in the body and prepare the body to receive the transplant graft. Giving allogeneic Orca-Q may be safe, tolerable, and\u002For effective in treating patients with relapsed or refractory (R\u002FR) high-risk multiple myeloma.",[316,317],"Recurrent Multiple Myeloma","Refractory Multiple Myeloma",[319],"ORCA-Q","2026-08-05",{"date":322,"type":38},"2026-08-12",{"date":324,"type":20},"2026-09-01",{"date":326,"type":20},"2033-09-01",{"name":44,"class":45},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":335,"minAge":17,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":21,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":46},"100585828","comparison-of-new-surecore-biopsy-of-needle-to-standard-of-care-during-transperineal-prostate-biopsies-100585828","NCT06907446","Comparison of New SUREcore Biopsy of Needle to Standard of Care During Transperineal Prostate Biopsies","Comparison of BARD Max Core 18g Needle With Uro1 SUREcore 18g Needle in Targeted Prostate Biopsies","Inclusion Criteria:\n\n* Patient older than age of 18 undergoing prostate biopsy\n\nExclusion Criteria:\n\n* Unable to consent\n* Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives\n* Prisoners","MALE",{"count":337,"type":20},50,[23],"To study a novel biopsy needle system for performing transperineal prostate biopsy. Prostate biopsy remains the standard approach for prostate cancer detection. While pre-biopsy MRI allows for targeting of visible lesions, systemic or 'off target' samples are recommended due to the well-recognized risk of undegrading and under sampling with current commercially available needles. The SureCore plus single-use biopsy needle produces a more intact tissue core with a same caliber 18g needle with \\~21% more tissue per core in pre-clinical studies. This research study will determine if a new biopsy needle designed to produce more robust tissue cores per sample can improve detection and characterization of prostate cancer.",[341],"Prostate Cancer","2026-08-04",{"date":344,"type":38},"2026-08-06",{"date":346,"type":38},"2025-05-01",{"date":348,"type":20},"2027-12-01",{"name":44,"class":45},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":83,"sex":84,"minAge":356,"maxAge":357,"enrollmentInfo":358,"targetDuration":4,"studyType":21,"phases":360,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":370,"locationsCount":46},"100552723","the-influence-of-chardonnay-marc-intake-on-gut-and-cardiometabolic-health-100552723","NCT06476795","The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health","Inclusion Criteria:\n\n* Postmenopausal female, with a cessation of menses for at least 2 years\n* 45-70 years of age\n* BMI 25- 49.9 kg\u002Fm2\n* Fasting triglycerides \\> 120 mg\u002FdL\n* Subject is willing and able to comply with the study protocols and procedures.\n\nExclusion Criteria:\n\n* Self-reported use of daily anticoagulation agents including aspirin, NSAIDs\n* Prescription medications and supplements, except for a 6 month stable dose of thyroid medications\n* Vegan, Vegetarians, food faddists or those consuming a non-traditional diet\n* Fruit consumption ≥ 3 cups\u002Fday\n* Vegetable consumption ≥ 4 cups\u002Fday\n* Coffee\u002Ftea ≥ 3 cups\u002Fday\n* Dark chocolate ≥ 3 oz\u002Fday\n* Self-reported restriction of physical activity due to a chronic health condition\n* Self-reported chronic\u002Froutine high intensity exercise\n* Blood pressure ≥ 140\u002F90 mm Hg\n* Self-reported renal or liver disease\n* Self-reported heart disease, which includes cardiovascular events and stroke, diabetes\n* Peripheral artery disease Raynaud's syndrome or disease\n* Inability to properly place or wear the PAT probes or abnormal measurements on pre-screening PAT\n* Self-reported cancer within past 5 years\n* Self-reported gastrointestinal disorders, apart from appendix removal\n* Unwillingness to stop any supplement use, including herbal, plant or botanical, fish oil, oil supplements six weeks prior to study enrollment.\n* Indications of substance or alcohol abuse within the last 3 years\n* All forms of smoking (e.g. vaping, cigarette, cannabis)\n* Current enrollee in a clinical research study.","45 Years","70 Years",{"count":359,"type":20},5,[23],"Recently a dietary recommendation of 400 - 600 mg\u002F day has been proposed for the reduced risk of developing cardiovascular disease. Dietary flavanols can be obtained from the intake of foods such as tea, cocoa, wine, berries and apples. Incorporating Chardonnay Marc (the skins and seeds of Chardonnay grapes) into the diet can be an additional source of dietary flavanols. Like other flavanol-rich foods, Chardonnay Marc provides fiber and polysaccharides that may benefit gut health. This study seeks pilot data on the impact of the daily incorporation of Chardonnay Marc powder into the diet on markers of gut and cardiometabolic health.",[363,364,365],"Cardiovascular Diseases","Adiposity","Cardiometabolic Syndrome",{"date":295,"type":38},{"date":368,"type":38},"2024-06-01",{"date":72,"type":20},{"name":44,"class":45},{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":85,"enrollmentInfo":377,"targetDuration":4,"studyType":21,"phases":378,"briefSummary":379,"conditions":380,"keywords":382,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":384,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":46},"100500287","sleep-architecture--cognition-in-focal-epilepsy-100500287","NCT05794295","Sleep Architecture & Cognition in Focal Epilepsy","Inclusion Criteria:\n\n* Age 18 - 40 years of age\n* Focal Epilepsy\n* Capacity to fully cooperate and follow directions\n* no other significant neurological disorders which could affect cognition\n\nExclusion Criteria:\n\n* Current use of any medications that can significantly affect cognition\n* No severe sleep apnea",{"count":193,"type":20},[23],"Focal Epilepsy (FE) patients and healthy controls will wear an actigraph at home for one week and a home sleep study device at home for one night. Participants will then undergo two nights of testing (at least one week apart) at California Sleep Solutions (CSS) in Sacramento, CA. During the overnight stays, participants will have EEG leads placed and possibly a headband. They will undergo cognitive testing before they go to sleep and again in the morning. During one night of testing, sounds will be played in the room (acoustic stimulation). The sounds should not wake the participants.",[381],"Focal Epilepsy",[383],"Epilepsy",{"date":295,"type":38},{"date":386,"type":38},"2025-01-24",{"date":388,"type":20},"2028-06",{"name":44,"class":45},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":16,"minAge":398,"maxAge":286,"enrollmentInfo":399,"targetDuration":4,"studyType":21,"phases":400,"briefSummary":401,"conditions":402,"keywords":404,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":409,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":46},"100302753","virtual-reality-attention-management-100302753","NCT03221244","Virtual Reality Attention Management","Virtual Reality Attention Management Program for Improving Attention in Children","VRAM","Inclusion Criteria:\n\n* Significant (T score \\>= 60) ratings of Cognitive Problems\u002FInattention or DSM Inattention scale scores on the Conners' Parent or Teacher Rating Scale-3 or Parent ADHD Rating Scale-IV (ADHD-RS)\n* Endorsement of 4 or more symptoms of inattention on a clinical psychiatric interview (e.g. Parent DISC, DICA, Kiddie-SADS, Mini-KID)\n* Comfortable using a computer\n* Full Scale IQ \\> 80\n\nExclusion Criteria:\n\n* Psychosis (by parent report at phone screen), significant depression, autism (15 or \\> on Social Communication Questionnaire (SCQ)), psychotic disorders, visual or hearing impairment or any other disorder that may interfere with task performance\n* It is in the investigator's opinion that it is not in the subject's best interest to continue\n* Subject is non-compliant with training schedule\n* Subjects on pharmacotherapy for ADHD at the time of enrollment will be excluded from Aims 3 and 4.\n* Subjects starting behavioral or psychological treatment for ADHD during the training phase of the study will be excluded","8 Years",{"count":337,"type":20},[23],"Problems with distraction are widespread in the 21st century, but for people with developmental delays or behavioral challenges they can have more damaging effects. For example, susceptibility to distraction is associated with worse school and social performance, lower high school graduation rates, and increased incidence of serious accidents. The investigators' goal is to improve understanding of distractibility and develop a targeted treatment. The proposed intervention is based on models of habituation, which is a term that means reduced physiological and emotional response to a stimulus (e.g. moving object, or loud noise, etc.) as it is seen repeatedly. The investigators use virtual reality technology to show study participants distracting stimuli repeatedly in a virtual classroom setting, and their hypothesis states that participants will improve attention in the face of distraction by training with this technology intervention. The virtual classroom setting is especially relevant for children who have significant challenges with distractibility, such as children with ADHD. This intervention will likely be effective in helping individuals with other clinical disorders and perhaps the general population as well.",[403],"ADHD",[405,29,406,407,408],"Distractibility","Attention","Child","Pediatric",{"date":295,"type":38},{"date":411,"type":38},"2016-06-02",{"date":413,"type":20},"2027-07-02",{"name":44,"class":45},{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":423,"targetDuration":4,"studyType":21,"phases":425,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":434,"completionDateStruct":435,"leadSponsor":436,"locationsCount":46},"100609027","phase-2-ctdna-informed-management-of-early-stage-rectal-cancer-100609027","NCT07209215","ctDNA-Informed Management of Early-Stage Rectal Cancer","ULtra sensiTive ctDNA-Informed Management eArly-stage recTal cancEr (ULTIMATE)","ULTIMATE","Inclusion Criteria:\n\n* Tumor tissue histologically confirming rectal adenocarcinoma that is available for Natera ctDNA assay.\n* Cohort A only: Patients appropriate for receiving TNT including chemotherapy and chemoradiation.\n* Cohort B only: TNT must have included at least 4 cycles of CAPEOX or 6 cycles of FOLFOX and at least 45 Gy in 25 fractions to the pelvis during chemoradiation.\n* Patients ≥18 years of age at time of consent.\n* Ability to understand and willingness to sign the informed consent form (ICF).\n* Ability and stated willingness to adhere to the study visit schedule and protocol procedures\u002Frequirements.\n\nExclusion Criteria:\n\n* Prior treatment for rectal cancer, except for cohort B.\n* Evidence of distant metastatic disease on staging imaging (CT chest with abdominopelvic imaging by CT or MRI) within 8 weeks of enrollment.\n* Patients on hemodialysis.\n* Any condition that in the opinion of the investigator would interfere with the participant's safety or compliance while on trial",{"count":424,"type":20},200,[142],"This is a phase 2 pragmatic study to examine the utility of ctDNA-informed treatment management for participants with early-stage rectal cancer using the Signatera Genome assay. The primary aims are to 1) assess pathologic complete response (path CR) in the ctDNA informed management arm; 2) assess pathologic complete response (path CR) in the post total neoadjuvant therapy (TNT) standard of care (SOC) surgery arm; and 3) assess disease free survival (DFS) in the ctDNA informed management arm.",[428,429,430,431],"Rectal Adenocarcinoma","Rectal Cancer","Early-stage Rectal Cancer","Locally Advanced Rectal Adenocarcinoma","2026-08-03",{"date":320,"type":38},{"date":40,"type":20},{"date":42,"type":20},{"name":44,"class":45},{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":445,"targetDuration":447,"studyType":58,"phases":4,"briefSummary":448,"conditions":449,"keywords":456,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":46},"100649625","examining-relationships-between-musculoskeletal-function-measurements-of-movement-efficiency-and-nervous-system-function-after-chronic-stroke-100649625","NCT07737873","Examining Relationships Between Musculoskeletal Function Measurements of Movement Efficiency and Nervous System Function After Chronic Stroke","SOMADC-CC (SOMAtic Dysfunction Characterization Following Chronic Cerebrovascular Disease): Biomarker Study","SOMADC-CC","Inclusion Criteria:\n\n* • UC Davis Stroke Clinic outpatient patients \\>3 months from previous stroke\n\n  * Adults ≥18 years\n  * Previous admission diagnosis or referral indication:\n\n    o Ischemic stroke (prior history of)\n  * Able to sit upright, lie supine, and lie lateral recumbent left\u002Fright positions\n  * Must be able to walk independently with\u002Fwithout walking aids.\n  * Participants must have the capacity to consent to study participation themselves or have a Legally Authorized Representative (LAR) available.\n  * Willingness to receive SMS (text) messages and\u002For email to complete REDCap QoL survey\n\nExclusion Criteria:\n\n* • Acute skeletal fracture or known dislocation; history of pathologic (osteoporotic or neoplastic) skeletal fracture of thoracic cage, hip\u002Fpelvis\u002Fsacrum, or vertebral column\n\n  * Spinal column support brace (e.g. cervical collar)\n  * History of spinal cord injury with residual neuromuscular or sensory disability\n  * Clinical condition that would interfere with execution of movement or palpatory diagnostic testing, e.g. prohibitive chronic pain\n  * Participants who have received either OMT or chiropractic manipulation following their stroke and prior to enrollment.",{"count":446,"type":20},100,"1 Day","Stroke remains the leading cause of severe disability, and survivors frequently have incomplete recovery. More than half of older survivors have impaired mobility which contributes to poorer quality-of-life (QoL) and suffering. The annual rate of disability compared to myocardial infarction triples, and stroke accelerates natural age-related functional decline. Somatic dysfunction (SD) is impaired function of the body framework identified by physical examination. Few studies have rigorously studied SD among stroke survivors. We recently demonstrated the reliability of a novel, more construct valid osteopathic examination methodology \\[called the Functional Pathology of the Musculoskeletal System (FPMSS) model\\] to quantify SD among asymptomatic participants and patients with acute cerebral ischemia. The preliminary findings suggest that dysfunction may develop within the first week after acute ischemic stroke (IS) and be more severe among those with paralysis compared to healthy volunteers. The precise pathophysiologic mechanism underlying SD remains unknown.\n\nThe objective of this proposal is to establish the relationship between SD severity during chronic stroke recovery and physiologic biomarkers. The central hypothesis is that SD is quantifiable, correlates with biomarkers that reflect functional status, and is associated with QoL among chronic stroke survivors. There are currently no biomarkers that correlate with SD severity after IS. Establishing valid biomarkers associated with physiologic processes that are otherwise inferred by physical examination would allow for quantification of changes in response to treatment (e.g., osteopathic manipulative treatment; OMT) aimed at restoring economical biomechanical function. Testing this hypothesis will address several fundamental gaps in knowledge about osteopathic palpatory diagnosis, physiologic processes associated with SD, and its association with survivor outcomes. Until these knowledge gaps are filled, optimal strategies to complement stroke recovery in patients with neurological disability cannot fully be determined. The project specific aims are to quantify the association between SD among chronic (\\>3 months) IS survivors and measured (1) energy expenditure, (2) heart rate variability (HRV), and (3) patient-reported outcome (PRO) health domains.\n\nThe proposed research is significant because it will establish a novel osteopathic approach that determines the impact of whole musculoskeletal system (MSS) health on QoL among stroke survivors living with chronic disability and correlate physiologic properties related to SD. This approach will allow us to quantify SD and show meaningful associations with autonomic function, biomechanical economy, and QoL after chronic stroke. These new metrics would then be derived in stroke patients to determine SD and physiologic thresholds for those that would benefit most from OMT in a future trial. This proposal is innovative in that it seeks to shift current research and practice paradigms by re-appraising the impact of whole musculoskeletal functional economy on patient-centered outcomes among stroke survivors. Methodologically, use of the FPMSS model represents a novel, more construct valid, diagnostic paradigm to reliably identify SD and establish an osteopathic, cross-disciplinary approach to the field of stroke research. The model examines the MSS as integrated, highlighting proportionate, not merely symmetrical, posture and motion among survivors with chronic disability. Similarly, PROs have been used to quantify health status after stroke, but have not been used to study the relationship between chronic neurologic impairment and SD. Integrating contemporary patient-centered stroke outcomes, rigorous osteopathic assessment, and analysis of physiologic processes will advance our understanding of how musculoskeletal dysfunction impacts QoL after stroke.",[450,451,452,453,454,455],"Stroke","Osteopathic Medicine","Physical Examination","Heart Rate Variability (HRV)","Energy Expenditure","Patient Reported Outcome (PRO)",[457,458,459,460,461],"stroke","osteopathic medicine","patient reported outcome","heart rate variability","physical examination","2026-07-27",{"date":464,"type":38},"2026-07-30",{"date":466,"type":20},"2026-07-01",{"date":468,"type":20},"2028-06-30",{"name":44,"class":45},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":21,"phases":478,"briefSummary":479,"conditions":480,"keywords":484,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":491,"leadSponsor":492,"locationsCount":46},"100648086","supporting-mental-health-and-reducing-care-stress-in-caregivers-of-persons-with-cardiovascular-disease-100648086","NCT07717723","Supporting Mental Health and Reducing Care Stress in Caregivers of Persons With Cardiovascular Disease","Supporting Mental Health and Reducing Care Stress in Caregivers of Persons With Cardiovascular Disease: A Hybrid Effectiveness-Implementation Study of Caregiving Support in Cardiac Rehabilitation","Inclusion Criteria:\n\n* 18 years of age or older\n* Is a caregiver for a patient receiving care in our UC Davis Cardiac Rehabilitation Clinic. A caregiver is defined as someone who provides support to the patient with one or more basic or instrumental activities of daily living.\n* Has one or more caregiving-related challenges or issues that they would like support with\n* Is able to read and speak in English\n\nExclusion Criteria:\n\n* Is a paid professional caregiver with no family or fictive kin relationship with the care recipient\n* Has a diagnosis of major cognitive impairment or Alzheimer's or related dementias\n* Is unable to complete the protocol or participate in the intervention (e.g., unavailable during the intervention period, unable to access or use virtual meeting technology)",{"count":193,"type":20},[23],"The purpose of this study is to evaluate the preliminary efficacy, feasibility, acceptability, and barriers and facilitators to implementation of the Confident Caregiver intervention among family caregivers of persons with cardiovascular disease participating in cardiac rehabilitation. Caregivers receive four individualized intervention sessions focused on assessment of caregiving challenges, tailored coaching, stress reduction, education, and referrals to supportive resources. Outcomes include reductions in caregiving-related challenges, improvements in mental health, and reductions in stress.",[481,482,483,31,363],"Caregiver Burden","Stress","Depression",[485,486,487],"Cardiac Rehabilitation","Caregiver Support","Confident Caregiver","2026-07-23",{"date":462,"type":38},{"date":488,"type":38},{"date":275,"type":20},{"name":44,"class":45},{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":4,"eligibilityCriteria":499,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":500,"enrollmentInfo":501,"targetDuration":4,"studyType":21,"phases":503,"briefSummary":504,"conditions":505,"keywords":507,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":517,"leadSponsor":519,"locationsCount":46},"100601281","using-an-ai-mobile-application-to-promote-healthy-eating-100601281","NCT07108452","Using an AI Mobile Application to Promote Healthy Eating","Leveraging AI to Transform Dietary Choices for Cardiovascular Health in Young Adults Experiencing Food Insecurity","Inclusion Criteria:\n\n* Willing to use their smartphones with app to record all foods consumed\n* UC Davis student\n\nExclusion Criteria:\n\n* eating disorders\n* Participant in the validation study that tested the app's accuracy against weighed food records","24 Years",{"count":502,"type":20},114,[23],"The goal of this feasibility study is to determine the adherence, acceptability, and usability of the behavioral intervention of a mobile AI application and its effects on food choices and diet quality. A secondary goal is to assess whether the app's accuracy or feasibility differs by food security status. Study participants are UC Davis students aged 18-24 years. The main question it aims to answer is:\n\n\\- Does the gamified app version that delivers behavioral nudges have a higher adherence and acceptability rate, and does this translate to better dietary behaviors?\n\nParticipants will use either the intervention app (dietary assessment + gamification) or the control app (non-gamified, dietary assessment only) for six weeks to record all their food intake. Diet quality will be assessed at baseline and endline, and a Likert scale acceptability questionnaire will be administered at endline.",[506],"Healthy",[508,509,510,511,512],"artificial intelligence","Implementation science","college students","food security","diet quality","2026-07-15",{"date":515,"type":38},"2026-07-17",{"date":40,"type":20},{"date":518,"type":20},"2026-12",{"name":44,"class":45},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":83,"sex":16,"minAge":86,"maxAge":528,"enrollmentInfo":529,"targetDuration":4,"studyType":21,"phases":531,"briefSummary":532,"conditions":533,"keywords":535,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":539,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":543,"locationsCount":46},"100534307","effects-of-goji-vs-fiber-on-macular-degeneration-100534307","NCT06237127","Effects of Goji vs. Fiber on Macular Degeneration","Effects of Goji Berry Intake on Risk of Age-related Macular Degeneration: A Randomized Clinical Trial","GOJI","Inclusion Criteria:\n\n* Family history of AMD\n* Hyperlipidemia or managed diabetes\n* 65 - 95 years of age\n\nExclusion Criteria:\n\n* Dislike of, or allergy to, goji berries or any of the ingredients in the fiber-rich wafers and gummies (wheat, corn, oats, soy, natural orange flavor, xylitol, annatto, pectin, or other food ingredients)\n* Consumption of \\> 2 alcoholic drinks per day\n* Indications of substance or alcohol abuse\n* Current or planned use of a blood thinner (e.g., Coumadin, Warfarin) at any time during study\n* Use of multi-vitamin or any other supplements that contain lutein and\u002For zeaxanthin (if willing to stop the supplement, subject can be enrolled 6 months from stop date)\n* Taking any new medications started within the past 6 months, or changes in medication regimen planned in the next 6 months (stable use greater than 6 months is not exclusionary)\n* Any planned international travel during the study\n* Consuming \\>3 servings\u002Fday of a combination of spinach, kale, lettuce, orange bell peppers, corn, parsley, squash, broccoli, pumpkin, edamame\n* Regularly consuming \\>3 eggs\u002Fday\n* Currently participating in any other interventional research study\n* Diagnosed with inflammatory bowel disease, irritable bowel syndrome, other gastrointestinal disorder, undergoing cancer therapy or immunocompromised, or diagnosis of another condition where lutein, zeaxanthin and\u002For fiber supplementation would be contraindicated or would interfere with ability to participate in the study\n* Any physical characteristic or condition that precludes ability to perform study procedures\n* Medical or psychiatric condition that, in the opinion of the Investigator, would compromise study findings or prevent the participant from completing the study","95 Years",{"count":530,"type":20},60,[23],"The goal of this project is to conduct a clinical trial in 60 participants ranging from age 65-95 who are at risk for age-related macular degeneration (AMD). The study will evaluate the effects of 14g of goji berry intake or an equivalent amount and type of fiber, five days a week for six months, on visual health, gut microbiome profiles, skin carotenoid measures, and lipoprotein profiles.",[534],"Age-Related Macular Degeneration",[94,534,96,97,536,98,537,99,100,538],"Fiber","Gut Microbiome","Eye Health",{"date":515,"type":38},{"date":541,"type":38},"2024-04-29",{"date":156,"type":20},{"name":44,"class":45},{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":4,"eligibilityCriteria":550,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":551,"targetDuration":4,"studyType":21,"phases":553,"briefSummary":554,"conditions":555,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":558,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":46},"100443294","phase-1-fludarabine-and-cyclophosphamide-with-or-without-rituximab-before-cd19-chimeric-antigen-receptor-t-cells-for-the-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-100443294","NCT05052528","Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","A Phase I Study to Evaluate the Safety of Escalating Doses of Lymphodepleting Conditioning Chemotherapy Prior to CD19 Chimeric Antigen Receptor T Cells in Subjects With Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Commercial CD19 CAR T cell product not available for the patient\n* Male or female, aged \\>= 18\n* In good general health as evidenced by medical history or as determined by the principal investigator (PI)\n* Ability to swallow oral medication and willingness to adhere to the study intervention and any required medications\n* For females of reproductive potential: use of highly effective contraception (oral contraceptives, intrauterine device) during screening confirmed with serum pregnancy test, and agreement to use such a method during study participation and for an additional 4 weeks after the end of CD19 CAR T cell infusion\n* For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner\n* Agreement to adhere to lifestyle considerations throughout study duration including abstaining from tobacco and drug use\n* Subjects must have relapsed or refractory diffuse large B cell lymphoma treated with at least two lines of therapy Subjects must have failed to have a complete response, or have recurrent disease after the last treatment regimen. Subjects must have previously been treated with a regimen that includes an anthracycline and an anti-CD20 monoclonal antibody. Autologous transplant will be counted as one line of therapy\n* (CNS cohort) SSubjects must have primary or secondary CNS lymphoma and must fail to achieve a complete response (refractory disease), have progressive disease, or relapsed disease per the International Primary CNS Lymphoma Collaborative Group (IPCG) criteria following at least one prior line of therapy. First-line therapies include high dose methotrexate-based therapy but may also include temozolomide, high dose cytarabine,, lenalidomide, ibrutinib and rituximab. Radiation therapy, lenalidomide monotherapy and ibrutinib monotherapy are considered first line therapy if patient was not eligible for methotrexate-based chemotherapy at time of initial treatment but now meets study eligibility criteria\n* The patient's disease must be CD19 positive, either by immunohistochemistry or flow cytometry analysis on the last biopsy available\n* Age \\>= 18 years\n* Performance status: Adult Subjects: Eastern Cooperative Oncology Group (ECOG) \\>= 1; Subjects \\> 10 years of age: Karnofsky \\>= 80%; For CNS cohort, ECOG ≥ 2.\n* Absolute neutrophil count (ANC) \\>= 1000\n* Platelets \\>= 100\u002Fmm\\^3\n* Hemoglobin \\> 8 g\u002FdL\n* ANC \\>= 500 is acceptable if documented bone marrow involvement by disease\n* Creatinine clearance (estimated by Cockcroft Gault) or using 24 hour (hr) urine collection \\>= 50 cc\u002Fmin\n* Total bilirubin =\\\u003C 2 mg\u002FdL except in subjects with Gilbert's Syndrome in whom total bilirubin must be =\\\u003C 3.0\n* Alanine transaminase (alanine aminotransferase \\[ALT\\]\u002Fserum glutamic pyruvic transaminase \\[SGPT\\]) and aspartate aminotransferase (aspartate aminotransferase \\[AST\\]\u002Fserum glutamic oxaloacetic transaminase \\[SGOT\\]) =\\\u003C 3 x the upper limit of normal or =\\\u003C 5 x the upper limit of normal if documented liver involvement by disease\n* Cardiac left ventricular ejection fraction \\>= 45% as determined by an echocardiogram and no clinically significant electrocardiogram (ECG) findings\n* Baseline oxygen saturation \\> 92% on room air\n* Prior cancer directed therapy wash-out: at least 2 weeks or 5 half-lives, whichever is shorter must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis, except for radiotherapy within 10 days of apheresis, systemic corticosteroid use within 7 days of apheresis (with the exception of single dose for an allergic reaction), or any other immunosuppressive therapies within 7 days\n* No use of lymphodepleting agents including alemtuzumab and antithymocyte globulin for 7 days prior to peripheral blood collection, 5 days prior to CD19 CAR T cell infusion and for 90 days after infusion\n\nExclusion Criteria:\n\n* Presence of supplemental oxygen, cardiac pacemaker\n* Known allergic reactions to components of the anti-CD19 CAR T cell product as evidenced by prior documented anaphylactic reaction or other clinical signs and\u002For symptoms of an allergic reaction as determined by the PI\n* Febrile illness within 3 days of admission for lymphodepleting conditioning therapy\n* Treatment with another investigational drug or other investigational intervention within 2 weeks of apheresis\n* Primary immunodeficiency\n* History of autoimmune diseases (ex: Crohn's, rheumatoid arthritis, systemic lupus erythematosus, Sjogren's) resulting in end organ damage or requiring systemic immunosuppressive or systemic disease modifying agents within the last two years prior to enrollment\n* Autologous transplant within 6 weeks and allogeneic transplant within 3 months of planned CAR T cell infusion\n* Recipient of CD19 CAR T cell therapy outside of this protocol\n* Active central nervous system or meningeal involvement by tumor. Subjects with untreated brain metastases\u002Fcentral nervous system (CNS) disease will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with a history of CNS or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast-enhanced magnetic resonance imaging (MRI) for at least 30 days prior to study enrollment\n* History of active malignancy other than non-melanoma skin cancer, carcinoma in situ (e.g. cervix, bladder, breast)\n* Active human immunodeficiency virus (HIV) infection documented by positive viral load. HIV-positive patients with undetectable viral load are not excluded.\n* Subjects with uncontrolled concurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements\n* Pregnant or breastfeeding women are excluded from this study because CAR T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four (4) weeks after receiving the CAR-T cell infusion\n* Diagnosis of myelodysplasia on any bone marrow biopsy prior to initiation of therapy\n* Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded)",{"count":552,"type":20},36,[313],"This phase I trial evaluates the best dose, possible benefits and\u002For side effects of fludarabine and cyclophosphamide with or without rituximab before CD19 chimeric antigen receptor T cells in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or has not responded to previous treatment (refractory). T-cells are a normal part of the immune system. To make the T-cell medication, T-cells are taken from the blood and altered in a laboratory. They are then returned to the body. The altered T-cells will latch on to a specific part of the cancer cells and hopefully kill them. Once the T-cells have been altered in the laboratory, they are called \"CAR T-cells.\" CAR is short for \"chimeric antigen receptors.\" These are structures on the surface of cells that allow the altered T-Cells to find and destroy the cancer cells. Another part of the T-Cell medication is called \"CD19.\" This part is called a \"biomarker.\" Biomarkers help doctors determine whether a cancer is getting worse and whether medications are working to stop it. The chemotherapy drugs that are given before the T-Cell therapy are cyclophosphamide, fludarabine and rituximab. Rituximab is an immunotherapy drug. These chemotherapy drugs will reduce the number of normal (unaltered) T-Cells in the body to make room for the altered T-cells to kill the cancer cells. Giving fludarabine and cyclophosphamide with or without rituximab before CD19 CAR T cell therapy may help improve response to CD19 CAR T cell therapy in patients with diffuse large B-cell lymphoma.",[556,557],"Recurrent Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma",{"date":515,"type":38},{"date":560,"type":38},"2021-09-17",{"date":562,"type":20},"2027-12-15",{"name":44,"class":45},{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":16,"minAge":114,"maxAge":571,"enrollmentInfo":572,"targetDuration":4,"studyType":21,"phases":573,"briefSummary":574,"conditions":575,"keywords":576,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":46},"100623532","cognition-and-behavior-with-sham-accelerated-tms-100623532","NCT07397858","Cognition and Behavior With Sham Accelerated TMS","Studies of Cognition and Behavior Using Sham Accelerated Transcranial Magnetic Stimulation","Inclusion Criteria:\n\n* English speaking\n* Able to provide informed consent (and assent if \\\u003C 18 years)\n* 15-25 years old\n* Slight-to-severe symptoms of depression\n\nExclusion Criteria:\n\n* Past exposure to Transcranial Magnetic Stimulation\n* Unable to consent (due to medical condition, psychosis, substance use, etc)\n* Acute suicidal crisis or with active medical illness that would interfere with participation\n* Contraindications to receiving MRI as determined by screening questionnaires (Contraindications for MRI include metal in the body related to an injury or surgery, for example, surgical clips, metal fragments in the eyes, or piercings that cannot be removed. Subjects with braces or permanent retainers will not be scanned, because the effects on image signal are not well understood and may affect comparability between subjects and scan sites. Participants will be excluded for major neurological problems, such as seizure disorder, traumatic brain injury with loss of consciousness, or sensory problems that may impair task performance, such as blindness.)\n* Participation in any clinical study with exposure to any investigational treatment or product within the previous 30 days, or plan on concurrent participation in other studies","25 Years",{"count":7,"type":20},[23],"The goal of this clinical study is to understand how a person's expectations about treatment can influence their mood, motivation, and reactions to everyday rewards. The study includes young people ages 15-25 who will complete a sham (placebo) version of an accelerated transcranial magnetic stimulation (TMS) treatment. No active brain stimulation is given.\n\nThe main questions this study aims to answer are:\n\n1. Do expectancy and treatment beliefs change during and after an accelerated sham TMS schedule?\n2. Do these expectations influence mood, reward processing, or craving?\n3. Does a more intensive schedule of sham sessions lead to different expectancy effects than a slower, once-daily schedule?\n\nParticipants will:\n\n* Complete baseline clinical assessments and an MRI session\n* Undergo five days of accelerated sham TMS (no active brain stimulation is delivered)\n* Complete post-treatment MRI and follow-up assessments at 1 week and 4 weeks",[483],[577,578],"TMS","Sham TMS","2026-07-14",{"date":581,"type":38},"2026-07-16",{"date":583,"type":38},"2026-04-11",{"date":585,"type":20},"2028-01",{"name":44,"class":45},{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":594,"targetDuration":4,"studyType":21,"phases":596,"briefSummary":597,"conditions":598,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":607,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":46},"100607487","phase-1-tr-002-for-the-treatment-of-advanced-unresectable-metastatic-solid-tumors-unresectable-or-metastatic-refractory-pancreatic-adenocarcinoma-100607487","NCT07189195","TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma","A Phase 1 Study of Bisaminoquinoline Derivative (TR-002) for Injection for Advanced Treatment-Refractory Solid Tumors","Inclusion Criteria:\n\n* Aged 18 or over at the time of consent\n* Pathology or histology-confirmed metastatic or unresectable solid tumor for which standard systemic treatments are no longer effective or not tolerated\n* For the expansion cohort, participants must have pathology or histology-confirmed metastatic or unresectable pancreatic adenocarcinoma that is refractory and\u002For intolerant to all standard-of-care systemic treatments (including gemcitabine, nab-paclitaxel, fluoropyrimidine, oxaliplatin, and irinotecan)\n* Participants in dose escalation may have measurable and\u002For non-measurable disease. Imaging for disease assessment of measurable and non-measurable disease must be completed within 28 days prior to registration. Participants in dose expansion must have measurable disease per Response Evaluation Criteira in Solid Tumors (RECIST) 1.1\n* Adequate cardiac function, assessed by multiple-gated acquisition (MUGA) scan or echocardiography (left ventricular ejection fraction of \\> 50%)\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Absolute neutrophil count ≥ 1,000\u002FmcL\n* Platelets ≥ 75,000\u002FmcL\n* Hemoglobin ≥ 8g\u002FdL\n* Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (\\\u003C 3 x ULN in patients with known Gilberts)\n* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \\[SGOT\\])\u002F alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 3 × institutional ULN (\\\u003C 5 x ULN in patients with known liver metastases)\n* Creatinine ≤ 1.5 x institutional ULN OR glomerular filtration rate (GFR) ≥ 60 mL\u002Fmin\u002F1.73 m\\^2\n* For people of reproductive potential: use of highly effective contraception for at least 1 month prior to enrollment and agreement to use such a method through 3 months following the last dose of study treatment\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n\nExclusion Criteria:\n\n* Lactating or pregnant patients or patients of reproductive potential not willing to use effective methods of contraception\n* Clinically significant toxicities from most recent therapy or intervention prior to study enrollment that have not resolved to baseline or grade 1 (exceptions include alopecia and grade 2 sensory neuropathy)\n* Participant with a history of the following significant cardiovascular disease will be excluded:\n\n  * Participant has a history of myocardial infarction or unstable angina within 6 months prior to day 1.\n  * Participant has New York Heart Association (NYHA) Class II or greater congetive heart failure (CHF).\n  * History of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months prior to study treatment.\n  * Participant has cardiac arrhythmia, complete left bundle branch block, obligate use of a cardiac pacemaker, long QT syndrome or right bundle branch block with left anterior hemiblock (bifascicular block).\n  * History of congenital long QT syndrome or prolonged corrected QT interval (QTc) \\> 470 msec for females and males using Fridericia's formula (unless a pacemaker is in place or additional clinically non-significant condition such as bundle-branch block necessitating use of an alternate formula per cardiologist calculation) or uncorrectable abnormalities in serum electrolytes (i.e., sodium, potassium, calcium, magnesium, phosphorus). An average of triplicate readings for assessing QTc interval may be used\n* Active bacterial, fungal, and viral infection, as documented by positive culture, radiological imaging techniques, septic fever, or septic shock symptoms\n* Known hypersensitivity to 4-aminoquinolone compounds\n* Retinal or visual field changes of any etiology\n* History of psoriasis\n* History of porphyria\n* Known glucose-6-phosphate dehydrogenase (G6PD) deficiency\n* History of seizure disorder\n* Any other condition that could compromise the subject's safety or put the study outcomes at undue risk",{"count":595,"type":20},52,[313],"This phase I trial tests the safety, side effects and best dose of TR-002 for the treatment of solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), that cannot be removed by surgery (unresectable), that has spread from where it first started (primary site) to other places in the body (metastatic) and unresectable or metastatic pancreatic adenocarcinoma that does not respond to treatment (refractory). Chemotherapy drugs, such as TR-002, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. TR-002 may be safe and tolerable in treating patients with advanced, unresectable or metastatic solid tumors and unresectable or metastatic, refractory pancreatic adenocarcinoma.",[599,600,601,602,603,604,605,606],"Advanced Malignant Solid Neoplasm","Metastatic Malignant Solid Neoplasm","Metastatic Pancreatic Adenocarcinoma","Refractory Pancreatic Adenocarcinoma","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","Unresectable Malignant Solid Neoplasm","Unresectable Pancreatic Adenocarcinoma",{"date":581,"type":38},{"date":609,"type":38},"2025-11-07",{"date":611,"type":20},"2030-02-07",{"name":44,"class":45},{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":620,"enrollmentInfo":621,"targetDuration":4,"studyType":21,"phases":622,"briefSummary":623,"conditions":624,"keywords":630,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":637,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":641,"locationsCount":46},"100517368","phase-2-alendronate-for-osteonecrosis-in-adults-with-sickle-cell-disease-100517368","NCT06016634","Alendronate for Osteonecrosis in Adults With Sickle Cell Disease","A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease","Inclusion Criteria:\n\n* Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)\n* Ability to provide written informed consent\n* Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner\n* Negative urine pregnancy test for anyone of childbearing potential at study entry\n\nExclusion Criteria:\n\n* Pregnant women\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners\n* Hospitalizations (for any cause) within 2 weeks of study entry","80 Years",{"count":168,"type":20},[142],"A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis",[625,626,627,628,629],"Sickle Cell Disease","Sickle Cell Anemia","Osteonecrosis","Ischemic Necrosis","Avascular Necrosis",[631,632,633,634,635,636],"sickle cell disease","sickle cell anemia","osteonecrosis of the femoral head","hip osteonecrosis","ischemic necrosis of the femur","avascular necrosis of the femur",{"date":581,"type":38},{"date":639,"type":38},"2026-03-09",{"date":275,"type":20},{"name":44,"class":45},""]